GMAB Stock Forecast & Price Target

Genmab's stock outlook is positively supported by its robust sales performance of DARZALEX, which achieved worldwide net sales of $3.9 billion in 4Q25, exceeding both internal and consensus estimates. The expected royalities from DARZALEX have also been revised upwards to $722 million for 4Q25, underlining Genmab's strong financial fundamentals and capacity for profitability. Additionally, Genmab's extensive pipeline and solid positioning in the multiple myeloma treatment arena are indicative of potential near- and medium-term clinical data catalysts that may further strengthen its market position amidst challenges in the biotech sector.

Genmab faces multiple risks that contribute to a negative outlook on its stock, including slowing sales of its flagship product, Darzalex, and a failure to secure label extensions for the same. The company has also experienced disappointing results from crucial clinical trials, specifically for its product Epkinly, leading to reduced probabilities for its approval in various settings. Additionally, lower-than-expected market penetration for Epkinly and other products, along with potential dilution and macroeconomic concerns, further exacerbate the uncertainty surrounding Genmab's financial prospects.